ZBIO
Zenas BioPharma, Inc.
Price Chart
Latest Quote
$17.47
-0.91 (-4.95%)
Current Price
| Previous Close | $18.38 |
| Open | $18.33 |
| Day High | $18.92 |
| Day Low | $17.40 |
| Volume | 460,217 |
Stock Information
| Shares Outstanding | 63.13M |
| Total Debt | $266.83M |
| Cash Equivalents | $717.20M |
| Net Income | $-425.15M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.10B |
| EPS (TTM) | $-9.10 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $652.56M |
| Income | $-425.15M |
| Cash/sh | $11.36 |
| Employees | 167 |
Financial Ratios
| Quick Ratio | 11.74 |
| Current Ratio | 11.94 |
| Debt/Eq | 79.45 |
Returns & Margins
| ROA | -29.06% |
| ROE | -137.11% |
Ownership
| Insider Ownership | 23.20% |
| Institutional Ownership | 90.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.71 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $42.12 |
Technical Indicators
| SMA20 | $18.59 |
| SMA50 | $19.59 |
| SMA200 | $24.61 |
| RSI | 45.72 |
| ATR | 1.2877 |
| Shares Float | 39.62M |
| Short Float | 25.23% |
| Short Ratio | 21.92 |
| Rel Volume | 0.89 |
Performance History
| Week | -5.05% |
| Month | -16.13% |
| Quarter | -30.89% |
| 6 Months | -52.36% |
| YTD | -49.36% |
| Year | +82.93% |
| 10 Years | -3.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $17.47 | 476,392 |
| 2026-06-04 | $18.38 | 508,400 |
| 2026-06-03 | $17.40 | 415,800 |
| 2026-06-02 | $17.13 | 634,000 |
| 2026-06-01 | $18.17 | 636,700 |
| 2026-05-29 | $18.40 | 724,800 |
| 2026-05-28 | $18.56 | 733,800 |
| 2026-05-27 | $18.09 | 321,600 |
| 2026-05-26 | $18.73 | 406,600 |
| 2026-05-22 | $18.97 | 342,200 |
| 2026-05-21 | $19.84 | 531,800 |
| 2026-05-20 | $19.56 | 569,000 |
| 2026-05-19 | $17.84 | 659,000 |
| 2026-05-18 | $16.91 | 1,163,000 |
| 2026-05-15 | $18.34 | 642,900 |
| 2026-05-14 | $18.90 | 510,700 |
| 2026-05-13 | $19.93 | 516,400 |
| 2026-05-12 | $19.16 | 297,000 |
| 2026-05-11 | $20.40 | 384,500 |
| 2026-05-08 | $19.64 | 289,100 |
| 2026-05-07 | $19.27 | 448,500 |
| 2026-05-06 | $20.83 | 352,600 |
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
MT Newswires âĸ 2026-06-03T13:10:43ZA Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-01T12:06:54Z
Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings
TipRanks âĸ 2026-05-21T17:58:00Z
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss
Simply Wall St. âĸ 2026-05-13T17:28:10Z
Insiders Are Scooping Up These 2 âStrong Buyâ Stocks
TipRanks âĸ 2026-04-08T10:01:20Z
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk
Simply Wall St. âĸ 2026-03-29T05:05:45Z
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires âĸ 2026-03-27T19:52:08ZSector Update: Health Care Stocks Retreat Friday Afternoon
MT Newswires âĸ 2026-03-27T17:47:23ZWall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of Hormuz
MT Newswires âĸ 2026-03-27T13:17:01ZENAVATE's Zenas Bio Pharma add Is a Footnote â The Obexelimab Pipeline Is What to Watch
Motley Fool âĸ 2026-03-21T18:23:19Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $10,000,000 | $5,000,000 | $50,000,000 | $0 |
| Operating Revenue | $10,000,000 | $5,000,000 | $50,000,000 | $0 |
| Expenses | ||||
| Interest Expense | $7,327,000 | $0 | - | - |
| Total Expenses | $221,385,000 | $168,888,000 | $77,147,000 | $75,199,000 |
| Other Income Expense | $-171,255,000 | $-644,000 | $-9,676,000 | $-44,083,000 |
| Other Non Operating Income Expenses | $417,000 | $202,000 | $624,000 | $61,000 |
| Net Non Operating Interest Income Expense | $4,824,000 | $7,973,000 | - | - |
| Interest Expense Non Operating | $7,327,000 | $0 | - | - |
| Operating Expense | $221,385,000 | $168,888,000 | $77,147,000 | $75,199,000 |
| General And Administrative Expense | $53,322,000 | $29,749,000 | $17,114,000 | $13,510,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Interest Income | $4,824,000 | $7,973,000 | - | - |
| Interest Income | $12,151,000 | $7,973,000 | - | - |
| Normalized Income | $-206,116,502 | $-156,319,660 | $-28,987,000 | $-75,138,000 |
| Net Income From Continuing And Discontinued Operation | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Total Operating Income As Reported | $-383,057,000 | $-163,888,000 | $-37,147,000 | $-76,199,000 |
| Net Income Common Stockholders | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income Including Noncontrolling Interests | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income Continuous Operations | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Pretax Income | $-377,816,000 | $-156,559,000 | $-36,823,000 | $-119,282,000 |
| Special Income Charges | $-171,672,000 | $0 | $-10,000,000 | $-1,000,000 |
| Interest Income Non Operating | $12,151,000 | $7,973,000 | - | - |
| Operating Income | $-211,385,000 | $-163,888,000 | $-27,147,000 | $-75,199,000 |
| Per Share | ||||
| Diluted EPS | - | $-11.89 | $-2.13 | $-9.26 |
| Basic EPS | - | $-11.89 | $-2.13 | $-9.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $-51,502 | $-177,660 | $-2,163,000 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-198,761,000 | $-155,576,000 | $-16,734,000 | $-30,977,000 |
| Total Unusual Items | $-171,672,000 | $-846,000 | $-10,300,000 | $-44,144,000 |
| Total Unusual Items Excluding Goodwill | $-171,672,000 | $-846,000 | $-10,300,000 | $-44,144,000 |
| Reconciled Depreciation | $56,000 | $137,000 | $113,000 | $78,000 |
| EBITDA (Bullshit earnings) | $-370,433,000 | $-156,422,000 | $-27,034,000 | $-75,121,000 |
| EBIT | $-370,489,000 | $-156,559,000 | $-27,147,000 | $-75,199,000 |
| Diluted NI Availto Com Stockholders | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Tax Provision | $-79,000 | $429,000 | $301,000 | $0 |
| Other Special Charges | $171,672,000 | - | $10,000,000 | $1,000,000 |
| Research And Development | $168,063,000 | $139,139,000 | $60,033,000 | $61,689,000 |
| Selling General And Administration | $53,322,000 | $29,749,000 | $17,114,000 | $13,510,000 |
| Other Gand A | $16,766,000 | $10,328,000 | $7,255,000 | $6,021,000 |
| Salaries And Wages | $36,556,000 | $19,421,000 | $9,859,000 | $7,489,000 |
| Diluted Average Shares | - | $13,198,960 | $17,415,875 | $12,879,648 |
| Basic Average Shares | - | $13,198,960 | $17,415,875 | $12,879,648 |
| Restructuring And Mergern Acquisition | - | $0 | $10,000,000 | $1,000,000 |
| Gain On Sale Of Security | - | $-846,000 | $-300,000 | $-43,144,000 |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $242,144,000 | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Total Assets | $383,640,000 | $369,968,000 | $68,180,000 | $74,579,000 |
| Total Non Current Assets | $32,469,000 | $14,045,000 | $8,376,000 | $6,135,000 |
| Other Non Current Assets | $218,000 | $217,000 | $186,000 | $212,000 |
| Non Current Prepaid Assets | $12,882,000 | $12,639,000 | $5,788,000 | $4,122,000 |
| Non Current Deferred Assets | $709,000 | $0 | $1,388,000 | $0 |
| Current Assets | $351,171,000 | $355,923,000 | $59,804,000 | $68,444,000 |
| Other Current Assets | $7,979,000 | $5,067,000 | $2,947,000 | $1,235,000 |
| Restricted Cash | $0 | $90,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $343,192,000 | $350,766,000 | $56,857,000 | $67,209,000 |
| Cash And Cash Equivalents | $110,641,000 | $319,742,000 | $56,857,000 | $67,209,000 |
| Cash Financial | - | - | $56,857,000 | $67,209,000 |
| Debt | ||||
| Total Debt | $1,326,000 | $1,003,000 | $21,113,000 | $1,527,000 |
| Long Term Debt And Capital Lease Obligation | $211,000 | $218,000 | $20,557,000 | $812,000 |
| Current Debt And Capital Lease Obligation | $1,115,000 | $785,000 | $556,000 | $715,000 |
| Long Term Debt | - | - | $20,300,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $141,496,000 | $57,510,000 | $293,901,000 | $266,865,000 |
| Total Non Current Liabilities Net Minority Interest | $78,847,000 | $218,000 | $270,643,000 | $240,898,000 |
| Other Non Current Liabilities | $78,636,000 | - | - | - |
| Current Liabilities | $62,649,000 | $57,292,000 | $23,258,000 | $25,967,000 |
| Payables And Accrued Expenses | $48,454,000 | $48,199,000 | $17,580,000 | $20,921,000 |
| Payables | $7,229,000 | $17,347,000 | $5,697,000 | $5,815,000 |
| Total Tax Payable | $118,000 | $211,000 | $301,000 | $0 |
| Income Tax Payable | $118,000 | $211,000 | $301,000 | $0 |
| Accounts Payable | $7,111,000 | $17,136,000 | $5,396,000 | $5,815,000 |
| Equity | ||||
| Common Stock Equity | $242,144,000 | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Total Equity Gross Minority Interest | $242,144,000 | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Stockholders Equity | $242,144,000 | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Gains Losses Not Affecting Retained Earnings | $-64,000 | $194,000 | $37,000 | $-41,000 |
| Other Equity Adjustments | $-64,000 | $194,000 | $37,000 | $-41,000 |
| Retained Earnings | $-765,128,000 | $-387,391,000 | $-230,403,000 | $-193,279,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $250,086,000 | $240,086,000 |
| Other | ||||
| Ordinary Shares Number | $54,485,518 | $41,793,412 | $39,792,381 | $39,792,381 |
| Share Issued | $54,485,518 | $41,793,412 | $39,792,381 | $39,792,381 |
| Tangible Book Value | $242,144,000 | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Invested Capital | $242,144,000 | $312,458,000 | $-205,421,000 | $-192,286,000 |
| Working Capital | $288,522,000 | $298,631,000 | $36,546,000 | $42,477,000 |
| Capital Lease Obligations | $1,326,000 | $1,003,000 | $813,000 | $1,527,000 |
| Total Capitalization | $242,144,000 | $312,458,000 | $-205,421,000 | $-192,286,000 |
| Additional Paid In Capital | $1,007,331,000 | $699,651,000 | $4,645,000 | $1,034,000 |
| Capital Stock | $5,000 | $4,000 | $0 | $0 |
| Common Stock | $5,000 | $4,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $211,000 | $218,000 | $257,000 | $812,000 |
| Current Capital Lease Obligation | $1,115,000 | $785,000 | $556,000 | $715,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,080,000 | $8,308,000 | $5,122,000 | $4,331,000 |
| Current Accrued Expenses | $41,225,000 | $30,852,000 | $11,883,000 | $15,106,000 |
| Investments And Advances | $17,272,000 | $0 | - | - |
| Net PPE | $1,388,000 | $1,189,000 | $1,014,000 | $1,801,000 |
| Gross PPE | $1,388,000 | $1,189,000 | $1,014,000 | $1,801,000 |
| Other Properties | $1,388,000 | $1,189,000 | $1,014,000 | $1,801,000 |
| Other Short Term Investments | $232,551,000 | $31,024,000 | $0 | - |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-207,351,000 | $-119,805,000 | $-30,546,000 | $-67,850,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-172,333,000 | $-119,674,000 | $-30,529,000 | $-65,652,000 |
| Cash Flow From Continuing Operating Activities | $-172,333,000 | $-119,674,000 | $-30,529,000 | $-65,652,000 |
| Operating Gains Losses | $107,000 | - | - | $13,268,000 |
| Investing Activities | ||||
| Capital Expenditure | $-35,018,000 | $-131,000 | $-17,000 | $-2,198,000 |
| Investing Cash Flow | $-251,886,000 | $-30,552,000 | $-17,000 | $-2,198,000 |
| Cash Flow From Continuing Investing Activities | $-251,886,000 | $-30,552,000 | $-17,000 | $-2,198,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $148,573,000 | $419,017,000 | $0 | $59,391,000 |
| Financing Cash Flow | $215,280,000 | $412,958,000 | $20,116,000 | $59,391,000 |
| Cash Flow From Continuing Financing Activities | $215,280,000 | $412,958,000 | $20,116,000 | $59,391,000 |
| Net Other Financing Charges | $62,335,000 | $-6,334,000 | - | - |
| Net Preferred Stock Issuance | $0 | $178,381,000 | $0 | $59,391,000 |
| Preferred Stock Issuance | $0 | $178,381,000 | $0 | $59,391,000 |
| Net Common Stock Issuance | $148,573,000 | $240,636,000 | $0 | - |
| Common Stock Issuance | $148,573,000 | $240,636,000 | $0 | - |
| Other | ||||
| End Cash Position | $110,641,000 | $319,832,000 | $56,943,000 | $67,295,000 |
| Beginning Cash Position | $319,832,000 | $56,943,000 | $67,295,000 | $75,795,000 |
| Effect Of Exchange Rate Changes | $-252,000 | $157,000 | $78,000 | $-41,000 |
| Changes In Cash | $-208,939,000 | $262,732,000 | $-10,430,000 | $-8,459,000 |
| Proceeds From Stock Option Exercised | $4,372,000 | $275,000 | $116,000 | $0 |
| Net Investment Purchase And Sale | $-216,868,000 | $-30,421,000 | $0 | - |
| Sale Of Investment | $200,887,000 | $6,000,000 | $0 | - |
| Purchase Of Investment | $-417,755,000 | $-36,421,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-35,000,000 | $0 | $0 | $-2,000,000 |
| Purchase Of Intangibles | $-35,000,000 | $0 | $0 | $-2,000,000 |
| Net PPE Purchase And Sale | $-18,000 | $-131,000 | $-17,000 | $-198,000 |
| Purchase Of PPE | $-18,000 | $-131,000 | $-17,000 | $-198,000 |
| Change In Working Capital | $951,000 | $25,431,000 | $-8,039,000 | $7,967,000 |
| Change In Other Current Liabilities | $-902,000 | $-673,000 | $-714,000 | $-717,000 |
| Change In Payables And Accrued Expense | $5,009,000 | $33,805,000 | $-3,976,000 | $13,145,000 |
| Change In Accrued Expense | $15,052,000 | $22,065,000 | $-3,558,000 | $12,055,000 |
| Change In Payable | $-10,043,000 | $11,740,000 | $-418,000 | $1,090,000 |
| Change In Account Payable | $-10,043,000 | $11,740,000 | $-418,000 | $1,090,000 |
| Change In Prepaid Assets | $-3,156,000 | $-7,701,000 | $-3,349,000 | $-4,461,000 |
| Other Non Cash Items | $179,874,000 | $1,527,000 | $11,026,000 | $31,580,000 |
| Stock Based Compensation | $26,347,000 | $10,821,000 | $3,495,000 | $737,000 |
| Amortization Of Securities | $-1,931,000 | $-602,000 | $0 | - |
| Depreciation Amortization Depletion | $56,000 | $137,000 | $113,000 | $78,000 |
| Depreciation And Amortization | $56,000 | $137,000 | $113,000 | $78,000 |
| Depreciation | $56,000 | $137,000 | $113,000 | $78,000 |
| Gain Loss On Sale Of PPE | $107,000 | $0 | - | - |
| Net Income From Continuing Operations | $-377,737,000 | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Issuance Of Debt | - | $0 | $20,000,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $20,000,000 | $0 |
| Net Long Term Debt Issuance | - | $0 | $20,000,000 | $0 |
| Long Term Debt Issuance | - | $0 | $20,000,000 | $0 |
| Gain Loss On Investment Securities | - | - | - | $13,268,000 |
Fetched: 2026-06-01